journal article·2026-05-22Open access

Master Regulator SMC1A, Stabilized by N6‐Methyladenosine Reader IGF2BP1, Promotes HCC Progression Through Facilitating Enhancer–Promoter Interaction of Nestin

Zhenxiang Peng, Diguang Wen, Lu Zeng, Lin Lv, Shengtao Liao, Wenguang Zhang, Zhechuan Mei, Chuanfei Li

Abstract

ABSTRACT HCC remains a leading cause of cancer‐related mortality, and effective therapies are limited. SMC1A, a core subunit of the cohesin complex involved in chromatin organization and transcriptional control, has not been fully characterized in HCC. SMC1A expression and prognostic value were analyzed using ICGC and single‐cell datasets, and validated in tissue microarrays and clinical specimens. Functional roles were examined in vitro, in vivo, and in patient‐derived organoids. Mechanistic studies combined transcriptomic, chromatin, and post‐transcriptional analyses to define downstream transcriptional regulation and upstream m6A‐dependent control. Therapeutic delivery was assessed using siRNA‐loaded LNPs. SMC1A was significantly upregulated in HCC and associated with poor prognosis. SMC1A knockdown suppressed proliferation, migration, invasion, and organoid growth, reduced tumor burden in xenograft and primary models, and promoted apoptosis. Nestin was identified as a transcriptional target of SMC1A; SMC1A facilitated enhancer–promoter interactions to activate Nestin transcription, and Nestin overexpression rescued malignant phenotypes after SMC1A depletion. Upstream, IGF2BP1 bound m6A‐modified regions within the SMC1A 3′‐UTR, stabilized SMC1A mRNA, and maintained the SMC1A–Nestin axis. Systemic LNP‐siSMC1A accumulated in the liver and inhibited tumor growth. SMC1A drives HCC progression through Nestin‐associated chromatin regulation and is maintained by IGF2BP1‐mediated m6A stabilization. LNP‐based silencing of SMC1A suppresses HCC.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA modifications and cancer · Epigenetics and DNA Methylation · Genomics and Chromatin Dynamics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Gastroenterology The Second Affiliated Hospital of Chongqing Medical University Chongqing China

Chongqing Municipal Health Commission Key Laboratory of Precision Diagnosis and Treatment of Liver Cirrhosis and Complications The Second Affiliated Hospital of Chongqing Medical University Chongqing China

Gastroenterology Affiliated Banan Hospital of Chongqing Medical University Chongqing China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Chongqing Municipality

References (97)

Show source-provided references
1. A Global View of Hepatocellular Carcinoma: Trends, Risk, Prevention and Management
2. 10.1001/jamasurg.2022.798910.1001/jamasurg.2022.7989 ↗
3. 10.1038/s41572‐020‐00240‐310.1038/s41572‐020‐00240‐3 ↗
4. 10.1016/S0140‐6736(25)00403‐910.1016/S0140‐6736(25)00403‐9 ↗
5. 10.1016/j.gene.2020.14461210.1016/j.gene.2020.144612 ↗
6. 10.1126/sciadv.abe551810.1126/sciadv.abe5518 ↗
7. 10.1186/s13046‐022‐02321‐510.1186/s13046‐022‐02321‐5 ↗
8. 10.1002/1873‐3468.1494910.1002/1873‐3468.14949 ↗
9. 10.1038/s41588‐022‐01223‐810.1038/s41588‐022‐01223‐8 ↗
10. 10.1038/s41568‐020‐0270‐110.1038/s41568‐020‐0270‐1 ↗
11. Cohesin Mutations in Cancer10.1101/cshperspect.a026476 ↗
12. 10.1186/s12876‐023‐02850‐z10.1186/s12876‐023‐02850‐z ↗
13. 10.1002/cam4.589110.1002/cam4.5891 ↗
14. 10.1002/ctm2.158710.1002/ctm2.1587 ↗
15. 10.1016/j.canlet.2016.10.04110.1016/j.canlet.2016.10.041 ↗
16. 10.1016/j.omtn.2021.08.00910.1016/j.omtn.2021.08.009 ↗
17. 10.1002/jgm.366110.1002/jgm.3661 ↗
18. 10.1186/s13046‐024‐02976‐210.1186/s13046‐024‐02976‐2 ↗
19. 10.3892/ijo.2016.369710.3892/ijo.2016.3697 ↗
20. Association of Structural Maintenance of Chromosome‐1A Phosphorylation With Progression of Breast Cancer10.3390/cells14020128 ↗
21. 10.1002/cam4.606810.1002/cam4.6068 ↗
22. 10.7150/ijbs.2469210.7150/ijbs.24692 ↗
23. 10.1126/science.155355810.1126/science.1553558 ↗
24. 10.1007/s00018‐018‐2794‐z10.1007/s00018‐018‐2794‐z ↗
25. 10.1111/cas.1269110.1111/cas.12691 ↗
26. 10.3748/wjg.v19.i1.4210.3748/wjg.v19.i1.42 ↗
27. 10.1177/1179554921103825610.1177/11795549211038256 ↗
28. 10.1016/j.ajpath.2013.11.01410.1016/j.ajpath.2013.11.014 ↗
29. 10.1016/j.jhep.2022.07.01910.1016/j.jhep.2022.07.019 ↗
30. 10.1038/s41467‐019‐12925‐910.1038/s41467‐019‐12925‐9 ↗
31. 10.1186/s13046‐015‐0163‐410.1186/s13046‐015‐0163‐4 ↗
32. 10.1371/journal.pone.017388610.1371/journal.pone.0173886 ↗
33. 10.1186/s12943‐022‐01500‐410.1186/s12943‐022‐01500‐4 ↗
34. 10.7150/thno.4934510.7150/thno.49345 ↗
35. 10.1038/s41556‐018‐0045‐z10.1038/s41556‐018‐0045‐z ↗
36. IGF2BP1 Promotes SRF‐Dependent Transcription in Cancer in a m6A‐ and miRNA‐Dependent Manner10.1093/nar/gky1012 ↗
37. The Oncofetal RNA‐Binding Protein IGF2BP1 Is a Druggable, Post‐Transcriptional Super‐Enhancer of E2F‐Driven Gene Expression in Cancer10.1093/nar/gkaa653 ↗
38. 10.1038/s41419‐020‐02967‐z10.1038/s41419‐020‐02967‐z ↗
39. 10.1177/101042831769592810.1177/1010428317695928 ↗
40. 10.1186/s40364‐023‐00499‐010.1186/s40364‐023‐00499‐0 ↗
41. 10.1038/s41572‐021‐00245‐610.1038/s41572‐021‐00245‐6 ↗
42. 10.1002/cncr.2997110.1002/cncr.29971 ↗
43. 10.1186/s40425‐018‐0462‐310.1186/s40425‐018‐0462‐3 ↗
44. AKT (v‐akt Murine Thymoma Viral Oncogene Homolog 1) and N‐Ras (Neuroblastoma Ras Viral Oncogene Homolog) Coactivation in the Mouse Liver Promotes Rapid Carcinogenesis by Way of mTOR (Mammalian Target of Rapamycin Complex 1), FOXM1 (Forkhead Box M1)/SKP2, and c‐Myc Pathways10.1002/hep.24736 ↗
45. 10.1093/nar/gkz43010.1093/nar/gkz430 ↗
46. 10.1093/nar/gky82210.1093/nar/gky822 ↗
47. 10.1016/j.xgen.2024.10069710.1016/j.xgen.2024.100697 ↗
48. 10.1093/nar/gkw10410.1093/nar/gkw104 ↗
49. 10.1093/nar/gkac94510.1093/nar/gkac945 ↗
50. 10.1093/nar/gkaa81110.1093/nar/gkaa811 ↗
51. 10.1038/s41578‐021‐00358‐010.1038/s41578‐021‐00358‐0 ↗
52. 10.1016/j.addr.2020.06.02610.1016/j.addr.2020.06.026 ↗
53. 10.1021/acs.molpharmaceut.2c0044210.1021/acs.molpharmaceut.2c00442 ↗
54. Engineered Ionizable Lipid Nanoparticles for Targeted Delivery of RNA Therapeutics Into Different Types of Cells in the Liver10.1126/sciadv.abf4398 ↗
55. 10.1021/acs.molpharmaceut.2c0003310.1021/acs.molpharmaceut.2c00033 ↗
56. 10.1016/j.jhep.2023.06.02110.1016/j.jhep.2023.06.021 ↗
57. 10.1053/j.gastro.2021.12.26910.1053/j.gastro.2021.12.269 ↗
58. 10.1038/s41416‐025‐02969‐810.1038/s41416‐025‐02969‐8 ↗
59. 10.1186/s12964‐024‐01595‐w10.1186/s12964‐024‐01595‐w ↗
60. 10.1101/gr.156570.11310.1101/gr.156570.113 ↗
61. 10.1016/j.xgen.2025.10077810.1016/j.xgen.2025.100778 ↗
62. 10.1016/j.celrep.2020.03.06710.1016/j.celrep.2020.03.067 ↗
63. 10.1016/j.omtn.2021.08.00910.1016/j.omtn.2021.08.009 ↗
64. 10.15252/msb.20221097910.15252/msb.202210979 ↗
65. 10.1038/s41588‐024‐01852‐110.1038/s41588‐024‐01852‐1 ↗
66. 10.1016/j.celrep.2020.10792910.1016/j.celrep.2020.107929 ↗
67. 10.1038/s41586‐020‐2151‐x10.1038/s41586‐020‐2151‐x ↗
68. 10.1038/s41588‐025‐02239‐610.1038/s41588‐025‐02239‐6 ↗
69. 10.1186/s13072‐025‐00598‐210.1186/s13072‐025‐00598‐2 ↗
70. 10.1038/nature0938010.1038/nature09380 ↗
71. Nestin Regulates Prostate Cancer Cell Invasion by Influencing the Localisation and Functions of FAK and Integrins
72. 10.1158/1541‐7786.MCR‐12‐051110.1158/1541‐7786.MCR‐12‐0511 ↗
73. 10.1038/cddis.2014.29310.1038/cddis.2014.293 ↗
74. 10.1016/j.cell.2016.05.05810.1016/j.cell.2016.05.058 ↗
75. 10.1186/s13046‐016‐0387‐y10.1186/s13046‐016‐0387‐y ↗
76. 10.1186/s12943‐024‐02013‐y10.1186/s12943‐024‐02013‐y ↗
77. 10.1016/j.clnves.2025.10002310.1016/j.clnves.2025.100023 ↗
78. 10.3389/fonc.2021.62956010.3389/fonc.2021.629560 ↗
79. 10.1016/j.clnves.2025.10000810.1016/j.clnves.2025.100008 ↗
80. 10.2147/OTT.S18095410.2147/OTT.S180954 ↗
81. 10.1111/jcmm.1695710.1111/jcmm.16957 ↗
82. 10.1002/hep.2968310.1002/hep.29683 ↗
83. 10.1016/j.tig.2021.06.01410.1016/j.tig.2021.06.014 ↗
84. 10.3389/fcell.2023.123635610.3389/fcell.2023.1236356 ↗
85. 10.1016/j.cellsig.2020.10991210.1016/j.cellsig.2020.109912 ↗
86. 10.1002/advs.20200283110.1002/advs.202002831 ↗
87. 10.1080/15476286.2020.181289410.1080/15476286.2020.1812894 ↗
88. 10.1186/s12943‐023‐01792‐010.1186/s12943‐023‐01792‐0 ↗
89. 10.1007/s11626‐023‐00812‐z10.1007/s11626‐023‐00812‐z ↗
90. 10.1016/S0140‐6736(18)30207‐110.1016/S0140‐6736(18)30207‐1 ↗
91. 10.1056/NEJMoa191574510.1056/NEJMoa1915745 ↗
92. 10.1101/gad.348314.12110.1101/gad.348314.121 ↗
93. 10.1158/1078‐0432.CCR‐18‐229310.1158/1078‐0432.CCR‐18‐2293 ↗
94. 10.1158/1078‐0432.CCR‐18‐377810.1158/1078‐0432.CCR‐18‐3778 ↗
95. 10.3389/fimmu.2023.122451610.3389/fimmu.2023.1224516 ↗
96. 10.1021/acscentsci.2c0010710.1021/acscentsci.2c00107 ↗
97. 10.1002/cam4.543210.1002/cam4.5432 ↗